COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
- - In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed - REHOVOT, Israel , May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained disciplined in optimizing costs and prioritizing initiatives that are designed to support a well-capitalized path forward in the best interest of our shareholders.
- 05/28/2025
|
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
- Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ -- According to a new market research report titled 'RWE Oncology Solutions Market by Component (Datasets, Consulting Services), Application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance), End User, and Geography - Global Forecast to 2035', the RWE oncology solutions market is projected to reach $3.51 billion by 2035, up from an estimated $893 million in 2025, growing at a CAGR of 14.7% during the forecast period. The growth of this market is mainly driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 Key Market Drivers and Trends The RWE oncology solutions market is witnessing strong growth, primarily driven by the shift towards patient-centric healthcare models and the adoption of cloud-based RWE platforms that are reshaping traditional evidence generation approaches. Integration of genomic and molecular data with real-time data collection and analysis is gaining momentum. Market expansion is further supported by the growing integration with precision medicine initiatives and the development of AI-powered analytics solutions, especially in developed markets with advanced healthcare infrastructure across pharmaceutical, regulatory, and healthcare provider domains. Latest trends in the RWE oncology solutions market include the development of comprehensive cancer datasets across the healthcare ecosystem and the industry's increasing focus on evidence-driven cancer care solutions. The market is increasingly focusing on robust, integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities to meet the demands of the rapidly evolving healthcare landscape. Growth Opportunities The market presents substantial growth opportunities in expansion in emerging markets, which offers substantial opportunities for market players looking to reach new customer bases. Another major opportunity lies in the integration with precision medicine initiatives, which enhances the accessibility of personalized cancer care. Additionally, the development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations increasingly seek evidence-based alternatives to traditional healthcare decision-making methods. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) – https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Market Challenges Despite significant growth potential, the overall RWE oncology solutions market faces challenges including data privacy and security concerns straining implementation budgets, particularly in cost-sensitive healthcare sectors. Limited interoperability between healthcare systems is creating integration barriers. Additionally, recent global disruptions have exposed vulnerabilities in data standardization processes, affecting data quality and completeness. Rapidly evolving regulatory compliance requirements across different regions are creating implementation concerns, and high implementation and maintenance costs, especially for comprehensive RWE platforms, are delaying adoption, limiting scalability in key healthcare markets. Segment Insights The global RWE oncology solutions market is segmented by component (Datasets [Disparate Datasets, Integrated Datasets], Consulting Services), application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance, Other Applications), end user (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). Market by Component The Datasets segment is expected to account for the largest share of the overall RWE oncology solutions market in 2025, primarily driven by increasing demand for comprehensive cancer data across the healthcare ecosystem, including disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries) and integrated datasets. Their comprehensive coverage, data reliability, and broad adoption across diverse healthcare applications make them indispensable in pharmaceutical research, regulatory submissions, and healthcare decision-making. However, the Consulting Services segment is expected to grow at the fastest rate through 2035, fueled by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services. Request a customized research analysis tailored to your specific requirements: https://www.meticulousresearch.com/request-customization/cp_id=5276 Market by End User The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to account for the largest share of the global RWE oncology solutions market in 2025, primarily due to their substantial investment in oncology R&D, regulatory requirements for post-market surveillance, and the essential requirement for real-world evidence capable of supporting drug development and regulatory submissions. However, the Healthcare Payers segment is expected to witness the highest growth rate during the forecast period, driven by increasing adoption of value-based care models, the need for cost-effectiveness evidence in coverage decisions, and increasing reliance on RWE for value-based healthcare decisions. Geographic Market Insights In 2025, North America is expected to hold the largest share of the global RWE oncology solutions market, followed by Europe, due to its advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, favorable reimbursement policies, and the strong presence of prominent RWE solution providers. Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. However, the Asia-Pacific region, particularly China, India, and South Korea, is projected to experience the fastest growth during the forecast period. This acceleration is mainly driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, increasing awareness about precision medicine approaches, and the region's pivotal role as a global pharmaceutical manufacturing center. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/view-pricing/590 Competitive Landscape The global RWE oncology solutions market is characterized by a competitive and dynamic landscape, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities. Market evolution is increasingly shaped by trends such as data standardization, integration of disparate data sources, and the development of AI-powered analytics solutions designed to address regulatory compliance across different regions. Leading companies are leveraging advanced data analytics capabilities to achieve comprehensive evidence generation without compromising data quality and are incorporating enhanced security measures to meet the demands of sensitive healthcare data systems. Key players in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others. Related Reports: Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954 Real-world Data (RWD) Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], End User (Pharma, Payers, Providers) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-data-market-5297 Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-evidence-analytics-market-5306 About Meticulous Research® We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight major sectors and 20+ geographic markets, all to deliver targeted business insights that help our clients lead in a rapidly evolving global market. With a strong focus on problem-solving for complex business challenges, our research enables organizations to navigate change with assertion, aligning it with strategic pathways for sustainable growth. By identifying innovative and effective solutions, we empower leaders to make impactful decisions that drive operational excellence and fuel innovation. We are committed to crafting insights that enhance business performance and help our clients unlock new revenue opportunities, positioning them for long-term success in the competitive global marketplace. To find out more, visit www.meticulousresearch.com or follow us on LinkedIn. Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected]Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Logo: https://mma.prnewswire.com/media/1757980/5251440/Meticulous_Research_Logo_1.jpg
- 05/27/2025
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
- REHOVOT, Israel , May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.
- 05/14/2025
|
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
- CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel , April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drug candidates with more effective, human-relevant methods. Importantly, CollPlant's Collink.3D ® portfolio of rhCollagen-based BioInk products can be utilized for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems, which serve as alternatives to animal testing.
- 04/15/2025
|
CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2024 Earnings Conference Call March 26, 2025 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Swayampakula Ramakanth - H.C.
- 03/26/2025
|
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
- CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.
- 03/26/2025
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel , March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets.
- 03/19/2025
|
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
- REHOVOT, Israel , Feb. 24, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, and hand tendons.
- 02/24/2025
|
CollPlant Biotechnologies Provides a Corporate Update
- - Additional patent granted for photocurable dermal filler- Update on AbbVie dermal filler program and achievement of contingent payment- Plan for cost reductions in place to extend cash runway REHOVOT, Israel , Feb. 12, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update. Photocurable Dermal Filler Program: Additional Patent Granted CollPlant today announced it has been granted U.S. Patent No.
- 02/12/2025
|
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript
- CollPlant Biotechnologies Ltd (NASDAQ:CLGN ) Q3 2024 Earnings Conference Call November 27, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Operator Greetings, and welcome to the CollPlant Biotechnologies Third Quarter 2024 Earnings Call. At this time all participants are in a listen-only mode.
- 11/27/2024
|
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- - Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel , Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter ending September 30, 2024, and provided a corporate update.
- 11/27/2024
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- - Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets.
- 11/12/2024
|
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
- CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
- 08/21/2024
|
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.
- 08/20/2024
|
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- - Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.
- 08/20/2024
|
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
- 3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time REHOVOT, Israel & EDEN PRAIRIE, Minn. , Aug. 19, 2024 /PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd.
- 08/19/2024
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets.
- 08/06/2024
|
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
- REHOVOT, Israel , July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023. The Company's first report details the initiatives that CollPlant has taken to adopt an ESG strategy with a focus on the pillars that represent the areas with the highest impact.
- 07/29/2024
|
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
- Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel , June 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks.
- 06/06/2024
|
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
- Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel , May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.
- 05/29/2024
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- - Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets.
- 05/16/2024
|
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
- CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 05/10/2024
|
CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
- 04/04/2024
|
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
- 04/04/2024
|
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT REHOVOT, Israel , April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
- 04/04/2024
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- - Conference call to be held on Thursday, April 4, 2024, at 10:00 a.m. U.S. EDT - REHOVOT, Israel , March 26, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open.
- 03/26/2024
|
CollPlant Issues Letter to Shareholders
- REHOVOT, Israel , Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal. View as PDF Dear Shareholders, As we look toward a promising and exciting year ahead, I am proud to reflect on CollPlant's main achievements throughout 2023.
- 02/15/2024
|
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
- REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.
- 01/08/2024
|
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
- The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards a GLP preclinical pivotal study with commercial size implants REHOVOT, Israel , Jan. 2, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast.
- 01/02/2024
|
CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings.
- 11/29/2023
|
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
- Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Company is preparing to launch large-animal study with a commercial size breast implant by year-end Cash and cash equivalents totaled $29 million as of September 30, 2023, representing an estimated cash runway of at least two years Revenues of $10.7 million and operating loss of $2.4 million for the first nine months of 2023 Conference call to be held on November 29, 2023, at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , Nov. 29, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs. "This quarter, we continued to steadily advance our programs with modest cash use," said CollPlant's Chief Executive Officer, Yehiel Tal.
- 11/29/2023
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- - Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open.
- 11/09/2023
|
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
- - Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Potential Products - REHOVOT, Israel , Nov. 1, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market. U.S. Patent No.
- 11/01/2023
|
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative
- - As a new participant, the Company strengthens its commitment to operate sustainably and transition the regenerative and aesthetics medicine industry to sustainable alternatives - REHOVOT, Israel , Sept. 21, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it has joined the United Nations Global Compact, the world's largest initiative for sustainable and responsible corporate governance.
- 09/21/2023
|
CollPlant to Present at the H.C. Wainwright Annual Growth Conference
- REHOVOT, Israel , Sept. 5, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will participate at the H.C Wainwright Annual Growth Conference, to be held from September 11-13, 2023 in New York, NY.
- 09/05/2023
|
CollPlant Biotechnologies Ltd. (CLGN) Q2 2023 Earnings Call Transcript
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2023 Earnings Conference Call August 24, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
- 08/24/2023
|
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
- Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant's regenerative breast implants Readying breast implant study in large animals for initiation by year end Continued positive sales trajectory for 3D bioinks Cash and cash equivalents totaled $22.3 million as of June 30, 2023; cash runway extended with additional $10 million milestone payment received in July 2023 from AbbVie Revenues of $10.6 million and operating income of $5.7 million for the first six months of 2023 Conference call to be held on August 24, 2023 at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , Aug. 24, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs. "This quarter, we were very pleased to announce the achievement of an important milestone related to the dermal filler product developed in collaboration with our partner, AbbVie, for which we received a $10 million payment.
- 08/24/2023
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- - Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open.
- 08/09/2023
|
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- - Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open.
- 08/09/2023
|
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
- EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)---- $SSYS #3dprinting--Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys' P3 technology-based bioprinter and CollPlant's rh-Collagen-based bioinks.
- 04/04/2023
|
CollPlant Biotechnologies Ltd. (CLGN) Q4 2022 Earnings Call Transcript
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C.
- 03/29/2023
|
CollPlant: Expanding End-Market Opportunities
- Possesses only plant-based collagen product with multiple end-market opportunities. AbbVie relationship alone justifies the current valuation.
- 02/12/2023
|
CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy
- REHOVOT, Israel , Sept. 19, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company will make a presentation on "Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications" at the International Conference on Biofabrication on September 28 th.
- 09/19/2022
|
New Strong Sell Stocks for April 22nd
- BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022
- 04/22/2022
|
CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st
- REHOVOT, Israel, Oct. 14, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the Company's Deputy CEO & Chief Financial Officer Eran Rotem, will present a company overview at the Dawson James 6th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida. Mr.
- 10/14/2021
|
CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs
- REHOVOT, Israel, Oct. 11, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that its recombinant human collagen (rhCollagen)-based bioink was used successfully by researchers from Israel's Technion Institute of Technology to create a 3D bioprinted implantable tissue containing a network of blood vessels capable of supplying blood to the implanted tissue. "We are excited with the impressive and innovative work of our collaborators at the Technion," said Yehiel Tal, CollPlant's CEO.
- 10/11/2021
|
CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors
- REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan.
- 08/19/2021
|
CollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Organs at the Biomaterials For 3D Printing Webinar
- REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Dr. Nadav Orr, Vice President of R&D, will present on August 19, 2021, an overview on the use of collagen Bionks for 3D Bioprinting, during the Biomaterials For 3D Printing webinar by 3DHEALS LLC. The presentation is titled "Collagen BioInk Platform for 3D Bioprinting of Tissues and Organs.
- 08/16/2021
|
CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company
- CLGN's platform-technology is underscored by its recent AbbVie partnership. Royalty model company that is debt-free, and well funded.
- 08/05/2021
|
Why 3D Systems, CollPlant BioTechnologies, and Stratasys Stocks Soared Today
- Five months ago, 3D Systems promised to expand into the "nascent industry" of printing entire human body parts. Today, it's doing just that.
- 06/22/2021
|
CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs
- REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its ordinary shares to the Nasdaq Global Select Market® effective at the open of market today, Friday, June 4, 2021. CollPlant's ordinary shares now trade under the Company's current ticker symbol "CLGN" and the Company's American Depositary Shares (ADSs) have been mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio.
- 06/04/2021
|
CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million
- REHOVOT, Israel, May 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on the Company's business developments. CollPlant reported revenues of $14.5 million for the first quarter of 2021, a 2,281% increase from the $609,000 recorded in the first quarter of 2020 resulting primarily from the $14 million upfront payment received from Allergan Aesthetics, an AbbVie company, in connection with the development agreement entered into in February 2021.
- 05/27/2021
|
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know
- CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $14.68 in the latest trading session, marking a +1.91% move from the prior day.
- 05/20/2021
|
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Stock Moves -0.22%: What You Should Know
- CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.77 in the latest trading session, marking a -0.22% move from the prior day.
- 05/11/2021
|
Is CollPlant Biotechnologies Ltd. Sponsored (CLGN) Stock Outpacing Its Medical Peers This Year?
- Is (CLGN) Outperforming Other Medical Stocks This Year?
- 04/07/2021
|
CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors
- REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members. U.S.-based Mr.
- 03/29/2021
|
CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2020
- REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures.
- 03/26/2021
|
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Dips More Than Broader Markets: What You Should Know
- CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.
- 03/23/2021
|
Has CollPlant Biotechnologies Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?
- Is (CLGN) Outperforming Other Medical Stocks This Year?
- 03/18/2021
|
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know
- In the latest trading session, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.33, marking a +1.76% move from the previous day.
- 03/17/2021
|
CollPlant Issues Letter to Shareholders
- REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders. Dear shareholders, What a year it has been – and how it has changed our way of life! All of us...
- 02/18/2021
|
CollPlant Announces Closing of $35.0 Million Registered Direct Offering of American Depositary Shares
- REHOVOT, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has closed the previously announced registered direct offering for the purchase and sale of an aggregate of 2,000,000 of the Company's American Depositary Shares (ADSs), at a purchase price of $17.50 per ADS. Each ADS represents one (1) ordinary share, par value NIS 1.50 per share, of CollPlant.
- 02/18/2021
|
Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today
- Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.
- 02/12/2021
|
CollPlant Announces $35.0 Million Registered Direct Offering of American Depositary Shares
- REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focused and other institutional investors for the purchase and sale of 2,000,000 of the Company's American Depositary Shares (ADSs), at a purchase price of $17.50 per ADS, in a registered direct offering. Each ADS represents one (1) ordinary share, par value NIS 1.50 per share, of CollPlant. The offering is expected to close on or about February 17, 2021, subject to satisfaction of customary closing conditions.
- 02/11/2021
|
Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Invest In Growth?
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 08/10/2020
|
We're Keeping An Eye On CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Rate
- Just because a business does not make any money, does not mean that the stock will go down. By way of example...
- 08/10/2020
|
Has CollPlant Holdings Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?
- Is (CLGN) Outperforming Other Medical Stocks This Year?
- 06/19/2020
|
Is CollPlant Holdings Ltd. Sponsored (CLGN) Outperforming Other Medical Stocks This Year?
- Is (CLGN) Outperforming Other Medical Stocks This Year?
- 06/03/2020
|
What Makes CollPlant Holdings Ltd. Sponsored ADR (CLGN) a New Strong Buy Stock
- CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 06/02/2020
|
CollPlant Biotechnologies Reports First Quarter (Q1) 2020 Financial Results
- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.
- 05/27/2020
|
Collplant to Host Webinar Highlighting its Plant-based, Human Recombinant Collagen (rhCollagen) Platform for the Future of Aesthetic and Regenerative Medicine
- CollPlant (NASDAQ:CLGN) , a regenerative and aesthetics medicine company, today announced that it will be hosting a webinar on Tuesday, May 12, 2020 at 11 am EDT/6 pm IDT that will feature its Co-Founder and Chief Scientist, Professor Oded Shoseyov and Chief Executive Officer, Mr. Yehiel Tal. The webinar will showcase the Company's journey to develop transformative patient solutions in regenerative and aesthetic medicine via its innovative plant-based, human recombinant collagen (rhCollagen) platform.
- 05/05/2020
|
CollPlant's Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.
- 04/24/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and Collplant Holdings (CLGN)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and
- 04/03/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX), Crinetics Pharmaceuticals (NASDAQ: CRNX) and Collplant Holdings (NASDAQ: CLGN)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
- 04/03/2020
|
CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2019
- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the full year ended December 31, 2019 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures
- 04/01/2020
|
7 Healthcare Stocks Worth Your Time Now
- These healthcare stocks have great financials now, and in the future. They all represent the future of medicine, and offer big growth.
- 03/09/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
- 02/25/2020
|
CollPlant Biotechnologies Raising $4.45 Million in U.S. Private Placement
- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative and aesthetic medicine company, announced it has entered into definitive agreements for up to $4.45 million. The capital raise is by way of a non-brokered private placement with U.S. accredited investors who have many years of deep experience in medical and 3D printing.
- 02/14/2020
|
CollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors
- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors as Chairman, effective immediately. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect.
- 02/10/2020
|
CollPlant Launches New Corporate Website to Showcase Recent Developments in Core Business Segments
- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the launch of its updated corporate website. The new website has a clean uncluttered design, improved functionality and enhanced rich content focused on the Company's growth into its core business segments: Medical Aesthetics and 3D Bioprinting of tissues and organs.
- 02/04/2020
|
3D Systems Joins CollPlant in Regenerative Medicine Efforts
- 3D Systems (DDD) and CollPlant aim to create state-of-the-art 3D bioprinters and BioInks to produce tissues and scaffolds.
- 01/14/2020
|
3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine
- Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN), announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry. The collaboration brings together two industry pioneers--3D Systems, renowned for its 3D printing technologies and healthcare expertise; and CollPlant, the developer of proprietary recombinant human collagen (rhCollagen) BioInk technology currently used for 3D bioprinting of tissues and organs. The two companies plan to jointly develop tissue and scaffold bioprinting processes for third party collaborators.
- 01/13/2020
|
CollPlant Partners in the Advanced Regenerative Manufacturing Institute
- CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI brings together a consortium of over 150 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.
- 01/06/2020
|
CollPlant Publishes Letter to Shareholders
- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, has issued a Letter to Shareholders, the full text of which follows below.
- 12/19/2019
|
CollPlant Holdings Ltd. Sponsored ADR (CLGN) Upgraded to Buy: Here's What You Should Know
- CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/05/2019
|
CollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update
- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-IFRS (non-GAAP) Measures" below.
- 11/29/2019
|
CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication's Industry Relations Committee
- REHOVOT, Israel, Oct. 22, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal was recently appointed as a member of the Industry Relations Committee of ISBF (International Society for Biofabrication).
- 10/22/2019
|
CollPlant to Present at Dawson James Small Cap Growth Conference on October 29, 2019 in Florida
- REHOVOT, Israel, Oct. 16, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal will present at the Dawson James 5th Annual Small Cap Growth Conference on Tuesday, October 29, 2019 at 1:10 p.m. ET. Mr. Tal will provide an overview of the Company's business, including in the fields of medical aesthetics including breast implants, and 3D bioprinting of tissues and organs.
- 10/16/2019
|
Top Ranked Momentum Stocks to Buy for October 11th
- Top Ranked Momentum Stocks to Buy for October 11th
- 10/11/2019
|
CollPlant Reports Second Quarter 2019 Financial Results and Provides Business Update
- REHOVOT, Israel , Sept. 26, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) , a regenerative medicine company, today announced financial results for the second quarter ended June 30, 2019 and provided an ...
- 09/26/2019
|
CollPlant Biotechnologies Closes on $5.5 Million Financing
- REHOVOT, Israel, Sept. 9, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced it has closed on a total of $5.5 million in convertible loans. A group of U.S. accredited investors with deep experience in the 3D printing industry purchased $3.5 million of the convertible loans, and the Company's largest shareholder, Ami Sagi, purchased $2.0 million of the convertible loans, through a non-brokered private placement. An additional $1.0 million investment will be made by Ami Sagi following the execution of a license and/or a co-development agreement between CollPlant and a strategic business partner, if such were to occur.
- 09/09/2019
|
CollPlant Biotechnologies to Present at the 21st Annual Rodman & Renshaw Global Investment Conference
- REHOVOT, Israel, Sept. 5, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Tuesday, September 10th, 2019 at 1:45 pm EDT. Mr. Tal will provide an overview of the Company's business, including in the fields of medical aesthetics, breast implants and 3D bioprinting of life saving organs. CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics.
- 09/05/2019
|
